igf-1 semaglutide Differential Role of Insulin/IGF-1 Receptor Signaling in Muscle Growth and Glucose Homeostasis Muscle loss and GLP-1R agonists

Arif T, Shteinfer-Kuzmine A, Shoshan-Barmatz V

Another phase IIa study was started in 2021 and is currently ongoing [13]

The trial compared the risk of Major Adverse Cardiovascular Event (MACE) between semaglutide and placebo when these were added to and used concomitantly with standard of care treatments for diabetes and cardiovascular disease

Years later, two new medications were approved by the FDA for weight loss: Wegovy in 2021 and Zepbound in 2024

In some embodiments, the otic formulation or composition comprises between about 0.001% to about 10% by weight of the therapeutic agent, or pharmaceutically acceptable prodrug or salt thereof